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Depression is an independent risk factor for cardiovascular diseases and is associated with metabolic syndrome (MetS). Levels of
plasminogen activator inhibitor-1 (PAI-1), an inhibitor of tissue-type and urokinase-type plasminogen activators, are associated
with MetS. To clarify the role of PAI-1 in subjects with long-term adverse mental symptomatology (LMS; including depression)
andMetS,wemeasuredcirculatingPAI-1levelsincontrols(n = 111),insubjectswithMetSandfreeofmentalsymptoms(n = 42),
andinsubjects withbothMetSandlong-termmentalsymptoms(n = 70).PAI-1increasedlinearlyacrossthethreegroupsinmen.
In logistic regression analysis, men with PAI-1 levels above the median had a 3.4-fold increased likelihood of suﬀering from the
comorbidity of long-term adverse mental symptoms and MetS, while no such associations were detected in women. In conclusion,
our results suggest that in men high PAI-1 levels are independently associated with long-term mental symptomatology.
1.Introduction
An increased prevalence of metabolic syndrome (MetS)
is a common ﬁnding among depressed patients [1]. Fur-
thermore, depression is an independent risk factor for the
development of cardiovascular diseases [2]. Nevertheless,
causal relationships between these factors remain unclear
[3],althoughseveralbehavioralorphysiologicalmechanisms
have been suggested [4]. According to previous studies,
increased serum plasminogen activator inhibitor-1 (PAI-
1) levels are associated with metabolic changes [5], and
possibly also with mental health problems [6]. Furthermore,
depressionisasigniﬁcantpublic healthcareissueworldwide,
and the incidence of metabolic syndrome is increasing
drastically. The relationship between these two conditions is
bidirectional [7]. Nevertheless, the factors regulating these
associations are unclear.
Plasminogen activator inhibitor-1 (PAI-1) is a major
physiological inhibitor of tissue-type (tPA) and urokinase-
type plasminogen (uPA) activators. It also possesses several
other roles in human physiology. PAI-1 belongs to the
family of serine protease inhibitors (SERPINs), and it is
an inhibitor of intravascular ﬁbrinolysis and cell-associated
proteolysis. Under normal physiological conditions, PAI-1
is synthesized by the liver, smooth muscle cells, adipocytes
and platelets [8]. However, in pathological conditions, such
as atherosclerosis, endothelial cells and other inﬂammatory-
stimulated cells secrete notable amounts of PAI-1 [8]. In2 Cardiovascular Psychiatry and Neurology
addition, abdominal obesity is related to elevated PAI-
1 plasma concentrations, and thus increased amounts of
adipose tissue might contribute to PAI-1 secretion, especially
in obese subjects [9]. Circulating PAI-1 is found in two
conformationally distinct forms: an active form, which has
a relatively short plasma half-life (∼30 min), and a latent
inactive form [10]. Binding to a carrier protein, vitronectin,
stabilizes the active form of PAI-1 [11]. PAI-1 is also found
in cerebrospinal ﬂuid [12]. tPA can cross the blood-brain
barrier(BBB)[13],andissynthesizedinseveralbrainregions
[14]. Furthermore, Yepes et al. reported that tPA increased
BBB permeability after ischemic stroke [15]. Whether PAI-1
itself is capable of crossing the BBB is currently unknown.
However, Hino et al. showed immunohistochemically the
localization of type 1 plasminogen activator inhibitor in
human brain tissues [16].
RecentﬁndingssuggestalinkbetweenelevatedPAI-1lev-
els and major depressive disorder (MDD) [17, 18]. However,
the role of metabolic syndrome was not assessed in these
studies. As PAI-1 is an independent and true component
of metabolic syndrome, we examined the additional eﬀect
of mental symptoms on the previously observed association
between metabolic syndrome and PAI-1. Moreover, the
possible gender diﬀerences have not been addressed in
previous studies. Thus, in the present study we examined
the role of long-term adverse mental symptoms (LMS) in
subjects with metabolic syndrome in the regulation of PAI-1
levelsinapopulation-basedsampleofbothmenandwomen.
2. Methods
2.1. Study Population. The present study was a part of
the longitudinal population-based Kuopio Depression Study
(KUDEP) in the central-eastern part of Finland [1, 19, 20].
The random general population sample (n = 3004) was
initially selected from the National Population Register in
1998. Study questionnaires were mailed to the subjects. The
baseline sample consisted of 2050 respondents aged 25–65
years. Follow-ups were performed in 1999 (n = 1722) and in
2001 (n = 1593). Altogether, 1347 subjects responded three
times.
The sample of the present study was from subgroups
of this 3-year followup study. The inclusion criteria for
the sample were based on the presence or absence of self-
reported mental symptoms prevailing at baseline and at both
follow-ups. First, we selected subjects who reported at least
one of the following at each followup: high Beck Depression
Inventoryscores(BDI-21score>9)[21],alexithymicfeatures
according to the Toronto Alexithymia Scale (TAS-20 score
>58) [22], or life dissatisfaction with the four-item Life
Satisfaction Scale (LS score >11) [23]. The mean BDI scores
(SD) for these subjects with long-term mental symptoms
(LMS group) were 14.7 (8.8) in 1998, 15.6 (10.0) in 1999,
and 15.2 (9.8) in 2001, indicating clinically signiﬁcant
prevailing depressive symptoms during the followup. A
control group of those not fulﬁlling any of these criteria at
any measurement point was formed. Their respective BDI
scores (SD) were 2.7 (2.7) in 1998, 2.9 (3.0) in 1999, and
2.4 (2.8) in 2001. There were no diﬀerences between these
groups in age or gender distributions (data not shown).
Seven years from the baseline, during clinical assess-
ment, the subjects in both sub-samples completed a ques-
tionnaire relating to their socio-demographic background.
The questionnaire included the following variables: age,
sex, and marital status (married or living with a partner
versus living alone). The subjects were also asked about
their smoking status (daily smoker: yes/no), frequency of
alcohol consumption (more than twice per week versus less),
previous physician-diagnosed illnesses, and whether they
had taken any psychotropic medication during the preceding
week. Data on the use of somatic medications during the
study period were obtained from the register of the National
Agency for Medicines and the Social Insurance Institute.
Depressive symptoms were assessed with the BDI [21].
For this study focusing on the relationships between
PAI-1, MetS, and mental symptomatology, the subjects were
further divided into three groups: (1) controls (subjects
without both MetS and LMS; 42 men and 69 women), (2)
c o n t r o l+M e t S( s u b j e c t sw i t hM e t Sb u tw i t h o u tL M S ;2 5
men and 17 women) and (3), LMS + MetS (subjects with
comorbid MetS and LMS; 42 men and 28 women). The
subjects with LMS but without MetS were omitted from the
current study.
Approval for the study was obtained from the Ethics
Committee of Kuopio University Hospital and the University
ofKuopio, andthestudy protocolwasinaccordancewiththe
latest version of the Declaration of Helsinki. All participants
providedwritteninformedconsentbeforeenteringthestudy.
2.2. Measurements. The laboratory measurements were car-
ried out in the laboratory of Kuopio University Hospital.
The subjects came for venous blood sampling at 8 am,
after having been instructed to fast for the previous 12
hours. Serum total cholesterol (TC), high-density lipopro-
tein cholesterol (HDL-C), triglyceride (TG), and fasting
plasma glucose measurements were carried out according
to routine protocols. Enzymatic methods (Thermo Electron
Co, Finland) were used for all measurements (TC: Konelab
CHOLESTEROL; HDL-C: Konelab HDL-CHOLESTEROL,
TG: Konelab TRIGLYCERIDES; fasting plasma glucose:
Konelab GLUCOSE). The total variations in the utilized
methods were 1.6%, 3.7%, 4.8%, and 3.1%, respectively.
The samples were analyzed using a Konelab 60i Clinical
Chemistry Analyzer (Thermo Electron Co.). Waist circum-
ference was measured at the midpoint between the lowest
rib and the iliac crest. A research nurse measured the blood
pressure after 10 minutes of rest in the sitting position at 2-
minute intervals. Systolic and diastolic blood pressures were
obtained as the mean of three measurements. Height and
body weight were measured in light clothing without shoes,
and the body mass index (BMI; kg/m2) was calculated.
MetS was diagnosed according to the modiﬁed crite-
ria of the National Cholesterol Education Program Adult
Treatment Panel III [NCEP ATP III; 1,19,20] based on the
presence of 3 or more of the following ﬁndings: fasting
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Figure 1: Serum PAI-1 levels in (a) men and (b) women. Data are expressed as means ± standard error of the mean. Statistical analysis was
performed with the Kruskal-Wallis test and post hoc testing between individual groups with the Mann-Whitney U-test. Only statistically
signiﬁcant P-values are shown.
≥1.7mmol/L, serum high-density lipoprotein cholesterol
(HDL-C) < 1.0mmol/L in men and <1.3mmol/L in women,
systolic blood pressure ≥130mmHg and/or diastolic blood
pressure ≥85mmHg, or waist girth >102cm for men and
>88cm for women.
ForPAI-1analyses,thevenousbloodsampleswerestored
at −80◦C until run. PAI-1 was analyzed with a human serum
adipokine LincoPlex kit (Millipore, MA, USA) using a Bio-
Plex Suspension Array System (Bio-Rad Laboratories Pty
Ltd; Hercules, CA, USA). Before the analyses, samples were
centrifuged for 15 minutes at 3000rpm. For the analyses
the samples were diluted in the appropriate sample matrix
to 1:400 according to the kit instructions. The assays were
performedaccording to the manufacturer’s instructions. The
intra-assay and interassay variations for analyses were <7.9%
and 21%, respectively.
2.3. Statistical Analysis. Diﬀerences between the study
groups were assessed using the chi-squared test for cat-
egorical variables and, when needed, exact P-values were
calculated with Fisher’s exact test. Due to the skewed
distribution of the PAI-1 data, the non-parametric Kruskal-





Logistic regression analysis (method: enter) was per-
formed to examine factors independently associated with
the likelihood of belonging to the LMS + MetS group. The
analyses were performed separately for men and women.
The regression model was adjusted for age, marital status,
alcohol consumption, daily smoking, cardiovascular disease
other than hypertension, and overweight (BMI ≥ 25). The
covariates were chosen based on the statistical signiﬁcance
between the groups (BMI, alcohol consumption, smoking,
marital status) and the known inﬂuence on PAI-1 levels
(BMI [5], cardiovascular disease [8]a n da g e[ 24]). A
median-based cut-oﬀ w a su s e df o rP A I - 1l e v e l si no r d e rt o
improve interpretability and optimize statistical power in the
analyses. PAI-1 medians were calculated separately for men
and women (men: median = 32.58ng/mL, lower median
half 0.00–32.13, upper median half 32.58–147.35; women:
median 28.11ng/mL, lower median half 0.00–28.05, upper
median half 28.16–115.38). In addition, as a second step, we
performed the same regression analysis using PAI-1 levels as
a continuous variable. Other covariates remained identical
to the ﬁrst model, and belonging to the group of LMS +
MetS was still the dependent variable. Two-tailed P-values
<.05 were considered to indicate statistical signiﬁcance in all
analyses, which were performed using SPSS software version
14.0 for Windows.
3. Results
Characteristics of the study population are described in
Table 1. BDI scores were highest in the LMS + MetS group
and BMI was lowest in the control group for both women
and men. In men, the highest number of current smokers
was observed in the LMS + MetS group, whereas the number
of frequent alcohol users was highest in the control group.
In women, the subjects in the LMS + MetS group were most
often living alone. The prevalence of cardiovascular disease
was low in all the groups.
Men belonging to the control + MetS group had higher
P A I - 1l e v e l sw h e nc o m p a r e dw i t hc o n t r o l s( m e a nv a l u e s :
43.42ng/mL (SEM 5.39) versus 29.76ng/mL (SEM 3.72),
P=.015; Figure 1(a)). Furthermore, the LMS + MetS group
had elevated PAI-1 levels compared with controls (mean
49.68ng/mL (SEM 5.28), versus 29.76ng/mL (SEM 3.72),
P=.003; Figure 1(a)). The mean increase in PAI-1 levels fol-
lowed a linear trend across the three groups (control, control
+ MetS, LMS + MetS; P=.002). Interestingly, PAI-1 levels
in women were similar in all groups (Table 1, Figure 1(b)).
Men had higher mean PAI-1 levels than women, but the
diﬀerence was not statistically signiﬁcant (men: 40.57ng/mL
(SEM 2.88); women: 34.58ng/mL (SEM 2.37), P=.236).
3.1. Eﬀect of Medications. The consumption of lipid-
lowering agents (mainly statins) did not diﬀer between the
groups for men or women (number (%) of male users:
controls 15 (36%), control + MetS 9 (36%), and LMS +4 Cardiovascular Psychiatry and Neurology













(n = 28) P-value∗
Age (years) 58.24 (1.61) 55.80 (2.19) 56.67 (1.35) .592 55.59 (1.17) 60.82 (1.79) 55.18 (1.84) .099
Marital status
(single) n (%) 4 (10) 3 (12) 8 (19) .430 5 (7) 1 (6) 9 (32) .004
Totalholesterol
(mmol/L) 4.92 (0.14) 4.96 (0.17) 5.02 (0.98) .891 5.19 (0.11) 5.17 (0.98) 5.03 (0.09) .750




× week) n (%)
13 (31) 1 (4) 10 (24) .034 6 (9) 4 (24) 3 (11) .258
Current smok-
ers n (%) 5 (12) 1 (4) 13 (31) .016 6 (9) 1 (6) 8 (29) .098
Cardiovascular
disease n (%) 0 (0) 2 (8) 2 (5) .223 5 (7) 1 (6) 3 (11) .358
Lipid-lowering
drugs n (%) 15 (36) 9 (36) 10 (24) .420 13 (19) 6 (35) 8 (29) .282
BDI score 2005 2.73 (0.42) 3.12 (0.56) 12.76 (1.48) <.001 3.86 (0.53) 2.59 (0.61) 13.54 (1.51) <.001
PAI-1 (ng/mL) 29.76 (3.72) 43.42 (5.39) 49.68 (5.28) .008 35.40 (3.07) 30.00 (5.01) 35.34 (5.21) .724
∗P values calculated with one-way ANOVA for age, total cholesterol, BMI, and the BDI score, with the Kruskal-Wallis test for PAI-1 and with the χ2 test for
alcohol consumption, smoking, marital status, cardiovascular disease, and the consumption of lipid-lowering drugs.
BDI: Beck Depression Inventory
BMI: Body mass index
SEM: Standard error of the mean.
MetS10(24%),P=.42;number(%)offemaleusers:controls
13 (19%), control + MetS 6 (35%), and LMS + MetS 8
(29%), P=.28). The consumption of lipid-lowering agents
did not aﬀect the mean total PAI-1 levels in men (men
consuming lipid-lowering drugs 40.05ng/mL (SEM 4.84)
versus not consuming 40.81ng/mL (SEM 3.59); P=.90), or
in women (34.64ng/mL (5.22) versus 34.56ng/mL (SEM
2.66), resp.; P=.99). The self-reported consumption of
antidepressants was similar in all groups for men (controls:
n = 4 (10%); control + MetS: n = 3 (12%); LMS + MetS:
n = 8 (19%); P=.43) and highest in control + MetS and
LMS + MetS groups for women (controls: n = 3( 4 % ) ;
c o n t r o l+M e t S :n = 5 (29%); LMS + MetS: n = 7 (25%);
P=.002). Those men using antidepressants had slightly
lower PAI-1 levels than the other men, but the diﬀerence
was not statistically signiﬁcant (37.00ng/mL (SEM 7.26)
versus 41.14ng/mL (SEM 3.15), resp.; P=.62). The opposite
ﬁnding was recorded in women, and there was a trend
towards statistical signiﬁcance (45.33ng/mL (SEM 9.56),
versus 32.95ng/mL (SEM 2.29), resp.; P=.08).
There were no signiﬁcant diﬀerences in the number of
women receiving sex hormones in the three study groups
(controls: n = 20 (29.0%); control + MetS: n = 7 (41.2%);
LMS + MetS: n = 7 (25.0%); P=.501). Furthermore, the
diﬀerence in mean PAI-1 levels between the women with
(n = 34) or without (n = 80) the use of sex hormones did
not reach statistical signiﬁcance (PAI-1: 30.41ng/mL (SEM
3.61) versus PAI-1: 36.35ng/mL (SEM 2.99), resp.; P=.253).
3.2. Multivariate Analyses. In logistic regression analysis,
men having PAI-1 levels above the median had 3.4-fold
higher risk for belonging to the LMS + MetS group (OR
3.40,95%CI1.23–9.40,P=.018)(Table 2),independentlyof
potential confounders. In addition, smoking and overweight
were independently associated with the likelihood of belong-
ing to the LMS + MetS group for men (OR 9.93, 95% CI
2.56–38.57; OR 3.85, 95% CI 1.04–14.21, resp.). However,
PAI-1 levels above the median did not predict mental
symptomatology in women (Table 2). In men, smoking
and overweight were independent predictors of MetS and
LMS (OR 9.93, 95% CI 2.56–38.57, P=.001 and OR 3.85,
95% CI 1.04–14.21, P=.043, resp.). These factors were also
signiﬁcant predictors in women (smoking OR 7.86, 95% CI
1.55–39.73,P=.013,andoverweightOR27.36,95%CI3.17–
235.77 and P=.003), and in women marital status was also
signiﬁcant (single OR 5.22, 95% CI 1.16–23.55, P=.032). As
asecondstep,weusedPAI-1levelsasacontinuousvariableto
assess the risk of long-term mental symptoms and MetS. The
results were essentially the same in men, as we observed that
eachoneunitincreaseinPAI-1levelsincreasedthelikelihood
of belonging to LMS + MetS group by 2.3% (OR 1.023,
95% CI 1.01–1.04, P=.008) in men. Furthermore, smoking
(OR 9.07, 95% CI 2.40–34.24, P=.001) and overweight (OR
4.33, 95% CI 1.17–16.00, P=.028) remained signiﬁcantly
associated with belonging to the LMS + MetS group in men.
In women, the same predictors were signiﬁcant as in the ﬁrst
model utilizing median cut-oﬀ of PAI-1 (smoking OR 7.47,Cardiovascular Psychiatry and Neurology 5
Table 2: Odds ratios (OR) with 95% conﬁdence intervals for the risk of the long-term mental symptoms and metabolic syndrome (LMS +
MetS) in men and women.
Men Women
OR 95% CI P-value OR 95% CI P-value
PAI-1 > median 3.40 1.23–9.40 .018 1.018 0.339–3.05 .975
Smoking 9.93 2.56–38.57 .001 7.86 1.55–39.73 .013
Overweight 3.85 1.04–14.21 .043 27.36 3.17–235.77 .003
Cardiovascular disease 1.72 0.17–17.57 .646 1.82 0.33–10.04 .492
Age 1.02 0.97–1.07 .373 0.97 0.91–1.04 .408
Marital status (single) 2.57 0.69–9.59 .160 5.22 1.16–23.55 .032
Alcohol more than 2 × week 1.07 0.37–3.08 .904 0.65 0.12–3.53 .617
95% CI 1.50–37.30, P=.014, overweight OR 28.17, 95% CI
3.25–243.78, P=.02 and marital status single OR 4.95, 95%
CI 1.09–22.45, P=.038).
4. Discussion
To the best of our knowledge, this is the ﬁrst study to
demonstrate the cumulative eﬀect of long-term adverse
mental symptoms and metabolic syndrome on serum PAI-
1 levels in men. However, no such diﬀerences could be
observed in women.
Elevated PAI-1 levels have been linked with depression
[17, 18, 25]. In addition, associations with vital exhaustion
[26–28] and anxiety with agoraphobia or social phobia
[29] have been reported. Furthermore, a single nucleotide
polymorphism (SNP) found in the PAI-1 gene was linked
to MDD and the antidepressant response [30]. The link
between depression and PAI-1 levels could be explained
by the inhibitory eﬀect of PAI-1 on tPA. tPA is the
main thrombolytic enzyme in blood, and it also promotes
pathways associated with synaptic plasticity and cell death
in the brain [15]. In addition, after ischemic stroke it also
increasesBBBpermeability[15].Brain-derivedneurotrophic
factor (BDNF), a member of the neurotrophin family that
regulates neuronal plasticity and survival, might explain the
connection between depression and the tPA system [31–33].
Direct evidence for PAI-1 crossing the blood-brain
barrier has not currently been established, but PAI-1 is
found in certain brain regions and in the cerebrospinal
ﬂuid [12, 16]. In patients with multiple sclerosis there is
a negative correlation between PAI-1 levels in CSF and
serum, which might suggest that there is an active transport
mechanism through the BBB [34]. Whether PAI-1 directly
causes the psychiatric symptoms in the central nervous
systemorwhethertheactionsareindirectormediatedviathe
modulation of the BBB by tPA system is currently unknown.
Most of the earlier reports on the association between
depression and the tPA system have been exclusively con-
ducted on male subjects. Exceptions include the studies of
Eskandari et al. [17] and Matthews et al. [25]o ny o u n g
premenopausal and perimenopausal women, respectively,
which yielded similar ﬁndings to those for men in other
studies. Hence, the gender diﬀerence found in the current
study is novel and warrants further investigation.
The use of simvastatin may reduce the expression of
the PAI-1 gene, and thereby reduce PAI-1 activity [35].
Moreover, other statins may have similar eﬀects [36]. Thus,
it has been suggested that statins might actually protect
against depression [37]. In our study population, total
cholesterol levels were similar in both genders. Furthermore,
nodiﬀerenceswereobservedintheuseofstatinsbetweenthe
groups for either gender, and the PAI-1 levels were similar
in subjects with or without the use of lipid-lowering drugs,
mainly statins.
Increased circulating PAI-1 is strongly linked to MetS
and is an independent component of the syndrome [38]. In
our sample, men with MetS (control + MetS) and LMS +
MetS had signiﬁcantly higher PAI-1 levels than controls, but
this diﬀerence was not seen in women. The ﬁndings in the
female sample require conﬁrmation in larger cohorts. How-
ever, in support of our ﬁndings, the correlations between
cardiovascular disease traits and circulating PAI-1 levels have
been shown to be greater in men than in women [39].
Postmenopausal women not receiving estrogen replacement
have been reported to have higher PAI-1 levels compared to
those on hormone replacement therapy [40]. Nevertheless,
although we were unable to speciﬁcally examine the eﬀect
of the menopausal status in the female sample, we observed
no diﬀerences in the levels of PAI-1 between women with or
without sex hormones.
Asalimitationofthestudy,wemeasuredtotalcirculating
PAI-1, not only the active form. However, in a recent
investigation in a similar assay to ours from the same vendor,
total and active PAI-1 correlated [41]. Thus, it could be
considered that the measurement of total PAI-1 reﬂects
the amount of active PAI-1. Nevertheless, a weakness of
the current study setting is the low number of subjects in
the study groups, which reduced the statistical power of
our analysis. Moreover, we used self-report questionnaires
instead of diagnostic criteria to evaluate adverse mental
symptoms. Utilizing diagnostic criteria might have provided
better comparability with other studies on the depression-
related biological alterations. Nevertheless, in line with our
study, dimensional rather than categorical (i.e., diagnosis-
based) evaluation of depression has been suggested [42].
In addition to the PAI-1 assay, measurement of serum tPA
couldhaveprovidedamorecomprehensiveassessmentofthe
prothrombotic status of the subjects [43].6 Cardiovascular Psychiatry and Neurology
In conclusion, high PAI-1 levels were associated with
long-term adverse mental symptoms in men, regardless
of the adjustment for potential confounders. No such
association was detected in women. Hence, increased PAI-1
levels might partly explain the association between MetS and
depression, as well as the increased risk for cardiovascular
illnesses in depressed subjects.
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